Article
HSP70 inhibition blocks adaptive resistance and synergizes with MEK inhibition for the treatment of NRAS-mutant melanoma.
Cancer research communications - 1 Oct 2021
Parris Joshua L D, Barnoud Thibaut, Leu Julia I-Ju, Leung Jessica C, Ma Weili, Kirven Nicole A, Poli Adi Naryana Reddy, Kossenkov Andrew V, Liu Qin, Salvino Joseph M, George Donna L, Weeraratna Ashani T, Chen Qing, Murphy Maureen E
Abstract excerpt
NRAS-mutant melanoma is currently a challenge to treat. This is due to an absence of inhibitors directed against mutant NRAS, along with adaptive and acquired resistance of this tumor type to inhibitors in the MAPK pathway. Inhibitors to MEK (mitogen-activated protein kinase kinase) have shown some promise for NRAS-mutant melanoma. In this work we explored the use of MEK inhibitors for NRAS-mutant melanoma. At...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.